MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis.

Purpose: MicroRNA-195 is dysregulated in different kinds of cancers and plays a pivotal role in tumorigenesis. It may function as a prognostic biomarker for cancers. However, the results from articles were not consistent. This study was designed to validate the prognostic value of microRNA-195 in human tumors.

Methods: We conducted a detailed search on PubMed until December 31, 2018. The quality of these publications was assessed on the basis of a list of key reviews presented by PRISMA statement. The pooled hazard ratios (HR) and pooled odds ratios (OR) of each 95% confidence interval (95% CI) were calculated to assess the effect.

Results: This meta-analysis included 12 studies involving 940 cancer patients to assess the prognostic value of miR-195 in different solid tumors. The results showed that patients with high expression of miR-195 had favorable tumor-node-metastasis (late vs early: pooled OR =0.16, 95% CI: 0.11-0.22, <0.001), lymph node metastasis (pooled OR =0.25, 95% CI: 0.18-0.35, <0.001) and distant metastasis (pooled OR =0.26, 95% CI: 0.13-0.52, <0.001). At the same time, high levels of miR-195 expression were closely correlated with better overall survival (pooled HR =0.46, 95% CI: 0.36-0.58, <0.001).

Conclusion: Elevated microRNA-195 may serve as a potential biomarker to predict a favorable prognosis for various cancer types in China.